Skip to main content
Premium Trial:

Request an Annual Quote

Inproteo Licenses His Tag Protein Purification Patent to Biogen

NEW YORK, Oct. 7 (GenomeWeb News) - Inproteo (formerly known as the Indiana Proteomics Consortium) said today that it has licensed US Patent No. 4,569,794 -- which protects a fusion protein purification technique known commonly as "His Tag" -- to Biogen.

"This license allows Biogen to have complete use of the technology for their research, development and commercialization activities," said Dr. John Hurrell, president of Inproteo.

Eli Lilly and Company, the original assignee on the patent, granted a license to Inproteo with exclusive right to issue sub-licenses, Inproteo said.

Inproteo said that a number of life science and biopharmaceutical companies have already concluded a licensing agreement and that the consortium is "holding discussions with numerous other companies, research institutes, and universities to license the patent for research and commercial use."

Inproteo was founded in 2002 as a collaboration between Indiana University, Purdue University, and Eli Lilly and Company.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.